Anne Rennea Simoneau

US Patent:

20020137797, Sep 26, 2002

Filed:

Aug 24, 2001

Appl. No.:

09/938846

Inventors:

Frank Meyskens - Irvine CA, US
Anne Simoneau - Long Beach CA, US
Eugene Gerner - Tucson AZ, US

International Classification:

A61K031/198

US Classification:

514/564000

Abstract:

The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.

US Patent:

20040162353, Aug 19, 2004

Filed:

Feb 17, 2004

Appl. No.:

10/780921

Inventors:

Frank Meyskens - Irvine CA, US
Anne Simoneau - Long Beach CA, US
Eugene Gerner - Tucson AZ, US

International Classification:

A61K031/198

US Classification:

514/564000

Abstract:

The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.

US Patent:

20040259813, Dec 23, 2004

Filed:

Apr 1, 2004

Appl. No.:

10/817449

Inventors:

Xiolin Zi - Irvine CA, US
Anne Simoneau - Long Beach CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K031/704
A61K031/4172
A61K031/405
A61K031/401
A61K031/12

US Classification:

514/025000, 514/400000, 514/419000, 514/423000, 514/518000, 514/534000, 514/679000

Abstract:

Compositions of matter and methods wherein chalcone and flavone derivatives are administered to human or veterinary patients for the treatment of bladder or urinary tract cancer. Compounds of the invention include 2′-hydroxy-4,4′,6′-trimethoxychalcone (Flavokawain A).